Purpose: In Genetic Absence Epilepsy Rats from Strasbourg (GAERS), age-related absence seizures start to appear from postnatal day (PN) 30 concomitant with 'spike and wave discharges' (SWDs) appearing on cortical EEG recordings. The aim of this study was to investigate the effect of early chronic levetiracetam (LEV) treatment on the development of SWDs in young and adult GAERS. Methods: From PN23 until PN60, LEV (54 mg/kg, i.p.) was administered once daily to GAERS (n = 8), while control GAERS (n = 7) received saline (0.9% NaCl, i.p.). All animals were implanted with four epidural EEG electrodes at PN51. EEG was recorded for 3 h daily, during the last 4 days of the treatment (PN57-PN60) and during 4 additional days after treatment had been terminated (PN61-PN64). The animals were monitored again at the age of 4 months (PN120-PN124), about 2 months after the last administration of LEV. Results: During treatment, epileptiform events in the LEV group were significantly reduced (62%, P < 0.05) in comparison with the control group. During the following 4 days, epileptiform events were reduced in the LEV group, with an average difference of 53% (P = 0.064). Once the animals had reached adult age, there was no difference in epileptiform events between the LEV group and controls. Conclusion: In this study, chronic LEV administration induced a reduction in epileptiform events in young GAERS. This effect persisted to some extent after treatment
Introduction
Every year the incidence of new epilepsy cases is between 26 and 70 per 100,000. 1 Despite the development of new pharmacological treatments, approximately one-third of epilepsy patients do not respond to anti-epileptic drugs (AEDs), and are referred to as refractory patients. 2 Treatments with anti-epileptogenic potential could modulate the processes underlying the development of epilepsy. Anti-epileptogenic properties have been attributed to some AEDs like valproate, 3 lamotrigine, 4 and pregabalin 5 as well as to vagus nerve stimulation. 6 Anti-epileptogenic effects of levetiracetam (LEV) in addition to anti-epileptic effects have been reported to appear in the rat amygdala kindling model for temporal lobe epilepsy 4, 7 and the Spontaneously Epileptic Rat (SER), a model of primary generalized epilepsy. 8 LEV is a novel well-tolerated AED approved as an adjunctive therapy for epilepsy patients with refractory partial seizures with or without secondary generalization. 9, 10 LEV has an anti-epileptic effect in a broad range of animal models mimicking both partial [11] [12] [13] and generalized epilepsy in man 11 including Genetic Absence Epilepsy Rats from Strasbourg (GAERS). 14 In contrast, LEV revealed no effect in the two conventional screening tests, namely the maximal electroshock and pentylenetetrazol models. 11 The mechanism of action of LEV differs from other AEDs and is as yet not fully elucidated.
Studies conducted on AEDs administered during the process of epileptogenesis have so far focused on animal models of acquired symptomatic epilepsy. 5, 15 In contrast, animal models of genetic idiopathic epilepsy have only been used scarcely. This study was stimulated by the ability of LEV to suppress seizure activity in animal models mimicking absence epilepsy in man. 14, 16, 17 Moreover, in a previous pilot study of chronic LEV administration to young GAERS, a preliminary indication of an antiepileptogenic effect was found. 16 Indeed, it was felt that investigating the effect of chronic LEV treatment in young GAERS could provide new insights and strategies for the treatment of epilepsy.
GAERS is an isomorphic and predictive model of absence epilepsy. The hallmark is the appearance of bilateral generalized 'spike and wave discharges' (SWDs) on the cortical EEG recordings during spontaneous absence seizures characterized by behavioral arrest. The first SWDs appear around postnatal day (PN) 30-PN40 and at the age of 4 months 100% of the GAERS have SWDs, which persist throughout the lifespan of the animal. 18 In the present study, we have investigated the effect of LEV on the age-related development of SWDs in GAERS by chronic administration of LEV (PN23-PN60) starting before the age of occurrence of SWDs. The effect of early chronic LEV administration on the development of SWDs was evaluated in young GAERS during treatment (PN57-PN60), immediately after treatment termination (PN61-PN64) and 2 months after the last LEV injection (age 4 months), when brain maturation was achieved and SWDs recorded on cortical EEG were numerous.
Methods

Animals
Fifteen GAERS were used in this study. The animals were born and raised under environmentally controlled conditions (12-h light/12-h dark cycles, lights on at 7:00 a.m., 20-22 8C) with food and water ad libitum at the animal facility of the Ghent University Hospital. All animals were treated according to the guidelines approved by the European Ethics Committee (decree 86/609/CEE). The study protocol was approved by the Animal Experimental Ethical Committee of Ghent University Hospital.
Surgery
The pups (n = 15) were randomly assigned to the two treatment groups: LEV and control group. LEV (54 mg/kg, provided by UCB Pharma, Belgium) was dissolved in saline (0.9% NaCl) and injected intraperitoneally (i.p.) in a dose-volume of 2 ml/ kg body weight, whereas control rats received an equivalent dose-volume of saline. From PN23 until PN60, LEV was administered once daily to eight GAERS, while the control GAERS (n = 7) received saline. All animals were weighed daily.
At age PN51, four epidural EEG stainless steel screw electrodes were bilaterally implanted over the fronto-parietal cortex of all 15 animals. The rats were anesthetized with ketamine/xylazine (80 and 7.5 mg/kg, respectively, i.p.) and additional ketamine (5 mg/kg, i.p.) was given when sensorial pain stimuli, by squeezing the footpad, elicited motor reflexes. One epidural electrode was positioned on the left side of the skull at height of the frontal cortex (AP = +2 mm, ML = +1.2 mm, referred to bregma) and one was placed on the right side of the parietal cortex (AP = À2 mm, ML = À1.2 mm, referred to bregma). The reference electrode was placed at lambda with the ground electrode on the left side of lambda (ML = +1.2 mm, referred to lambda). The EEG electrodes were fixed on the skull of the rat with acrylic cement. Lidocaine gel (2%) was applied at the incision wound and the rats were placed under a heating lamp until they had recovered from anesthesia.
EEG recording
EEG was recorded by means of a H2O
TM portable digital 32-channel EEG-recorder (Telefactor Corporation, USA). To avoid any interference with the circadian cycle, all recordings were performed during daytime (light period) starting at 10:00 a.m. in awake and freely moving animals. 19 Every 10 min, a standardized sound stimulus was provided to prevent the rats from falling asleep. 14, 20 During the recording sessions, the rats were continuously observed.
Effect of early chronic LEV administration on epileptiform events in young GAERS (PN57-PN64)
One week after surgery, the animals were placed in the EEG recording chambers and stayed there from PN56 (1 day before the start of the EEG recordings) until PN64 with food and water ad libitum. During the last 4 days of the treatment (PN57-PN60), EEG was recorded for 3 h daily. In this period, LEV or saline was injected 1 h after the start of the EEG recording. From PN61 on, treatment was halted, animals (controls and LEV group) received no longer injections and EEG was recorded during 4 additional days (PN61-PN64), 3 h daily (Fig. 1) . The EEG was recorded on several days to have a more robust dataset on the effect of LEV in these young animals.
Epileptiform events in young GAERS (PN57-PN64) were quantified by means of visual inspection of the EEG using TWIN TM off-line EEG analysis (Telefactor Corporation, USA) by an experienced electroencephalographer (SD). Young GAERS (under the age of 4 months) may not all have developed typical SWDs yet or have infrequent SWDs. 18 For quantification purposes, epileptiform events were classified into two closely related types, because the morphology of SWDs in young GAERS was found to be less pronounced and more variable when compared with SWD patterns in adult GAERS ( Fig. 2 ): (i) typical SWDs also present in adult GAERS (amplitude: >3 times baseline; peak frequency: 7-12 Hz; duration: >0.5 s) and (ii) SWD-like activity, which we have termed 'short irregular spike and wave discharges' (SISWDs), with clear spike and wave aspects characterized by lower amplitude (<3 times baseline amplitude) or lower peak frequency (5-7 Hz) and shorter in duration (<2 s). Only the numbers of different SWD types (SWDs and SISWDs) per hour were used as dependent values. The durations of SWDs and SISWDs were still very short in these young animals; therefore, relevant differences in discharge duration between treated and control animals could not be detected.
Evaluation of SWDs in adult GAERS (age 4 months) after chronic LEV treatment during early life
About the age of 4 months (range PN120-PN124), EEG was recorded for 1 day (duration of recording between 6 and 8 h) in 15 animals. For the analysis of the SWDs on the EEG of the adult GAERS, a previously described and validated detection software package was used. 21 Once a list of marked time instances was obtained by the detection method, a number of post-processing steps were performed Effect of LEV on the development of SWDs 405 by the software package: detections lasting less than 0.5 s were discarded and two detections less than 1 s apart were taken together. SWDs detected by the software package were visually confirmed. In these animals, both the number per hour and mean duration of the SWDs during the recording hours were calculated as well as the cumulative duration of the SWDs per hour (summation of the duration of all SWDs per hour). The software package specifically developed for the detection of SWDs was not appropriate for the scoring of the more irregular variant of the SWDs (SISWDs). Hence, the EEG was visually inspected for SISWDs, fulfilling the conditions described above, and the number per hour was calculated.
Statistical analysis
In young GAERS, statistical analysis was performed on both pooled and unpooled data. Data could be pooled after exclusion of interactions (hour Â treattreatment and day Â treatment) by ANOVA with repeated measurements. The number of SWDs and SISWDs per 3 h was taken together; this was termed the number of epileptiform events. Statistical analysis was also performed on unpooled data, which consisted of the number of typical SWDs and SISWDs per hour at the different time points during a total recording time of 24 h (3 h a day, during 8 consecutive days).
For the inter-group comparison between the LEV and control group the Mann-Whitney U-test was used. For the intra-group comparisons within the LEV and control group, a Friedman test was utilized. For the intra-group comparison between the mean number of epileptiform events on the two time points: during the last 4 days of treatment (PN57-PN60) and during the following 4 days after treatment had been terminated (PN61-PN64), a Wilcoxon signed rank test was used.
Through the further course of this paper (Results and Discussion Sections), the results obtained in young GAERS will be presented and discussed according to the recording periods: (a) the last 4 days of the treatment (PN57-PN60) and (b) the following 4 days after treatment cessation (PN61-PN64).
In adult rats, the Mann-Whitney U-test was used to compare the number per hour, the mean duration and the cumulative duration/hour of the SWDs between the LEV and control group. For SISWDs, the number per hour was compared between the LEV and control group using the Mann-Whitney Utest.
All statistical tests were performed utilizing the statistical software package SPSS 12. Data are presented as the mean AE the standard error of the mean (S.E.M.), and the significance level has been set at a = 0.05.
Results
Chronic administration of LEV during 38 days in young GAERS (PN23-PN60) did not induce growth changes. Normal body weight in LEV-treated GAERS (157 AE 8 g for males and 144 AE 10 g for females at PN60) was achieved in comparison with the control group (140 AE 15 g for males and 121 AE 6 g for females at PN60) treated with saline (NS, Student's t-test).
Effect of early chronic LEV administration on epileptiform events in young GAERS (PN57-PN64) LEV-treated rats (n = 8) showed less SWDs and SISWDs than control rats (n = 7) during treatment and also during the 4 days after the discontinuation of the treatment. During this 8-day recording period, typical SWDs were observed in three control rats. Only one of these rats had frequent (12 AE 2 per hour) SWDs on the EEG, which were short in duration (1.6 AE 0.2 s). None of the LEV-treated rats had typi-406 S. Dedeurwaerdere et al. cal SWDs; hence, there were too few SWDs to detect significant differences in SWDs between LEV and control group. SISWDs were observed in all rats. These SWD-like events were short lasting (<1.5 s) in the LEV and in the control group.
Effect of chronic LEV administration on epileptiform events during the last 4 days of the treatment period (PN57-PN60) During LEV treatment (PN57-PN60), the mean number of epileptiform events (pooled data) was 62% lower (P < 0.05, Mann-Whitney U-test) in the LEV group. The control group had a mean number of 86 AE 18 epileptiform events per 3 h, whereas this figure in the LEV group was 33 AE 11. Significant differences could also be found in the number of SISWDs (up to 81%) between LEV and control group on different time points during treatment (Fig. 3) . Also during the pre-injection hours (PN57-PN60), SISWDs were significantly lower in the LEV group (8 AE 2; 6 AE 2; 4 AE 2 and 7 AE 3) than in the control group (28 AE 8; 32 AE 6; 17 AE 6 and 20 AE 4) (Fig. 3) . Pre-and post-injection hours differed significantly in treated animals on PN59 and PN60 (Friedmand test) . Surprisingly, the number of SISWDs in the post-injections hours was higher than in the preinjection hour in the LEV-treated group (Fig. 3) . However, a trend of a higher number of SISWDs in the post-injection hours was also present in the control group on PN59 (P = 0.066; Friedman test).
No differences were found between the 4 individual days during treatment (PN57-PN60) within LEV and control group (data not shown, Friedman test).
Effect of chronic LEV administration on epileptiform events after treatment cessation (PN61-PN64)
When treatment was discontinued (PN61-PN64), there was a borderline missed reduction of 53% in the mean number of epileptiform events (P = 0.064, pooled data, Mann-Whitney U-test) in the LEV group compared with the control group. The control group had a mean number of 73 AE 14 epileptiform events per 3 h, whereas this figure in the LEV group was 34 AE 8. However, significant differences could be found in SISWDs (up to 66%) between LEV and control group at different separate time points (unpooled data, Fig. 3 ).
After treatment had been stopped, there were no differences between the recording hours within the LEV and the control group (Friedman test).
Within LEV and control group, there was a significant difference between the 4 days after treatment cessation (pooled data, Friedman test); this was manifested by an increase in the number of epileptiform events on the last 2 days of the recording period. In the LEV group, these number of epileptiform events on PN61-PN64 were, respectively, 25 AE 8, 23 AE 7, 40 AE 10 and 48 AE 9. In the control group, these figures were 52 AE 14, 57 AE 10, 94 AE 19 and 88 AE 19.
The Wilcoxon signed rank test did not reveal differences between the mean number of epileptiform events during treatment period and after treatment cessation in both groups (86 AE 13 versus 73 AE 14 for the control group and 33 AE 11 versus 34 AE 6 for the LEV group).
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Evaluation of SWDs in adult GAERS (age 4 months) after chronic LEV treatment during early life
At the age of 4 months all animals had typical SWDs. EEG recordings showed no significant difference between the LEV and control group in number, mean duration and cumulative duration of the SWDs (Mann-Whitney U-test). These numbers were only slightly lower in the LEV group (Fig. 4) . Also in SISWDs, no differences could be found between both groups (Fig. 4) . However, SISWDs were decreased substantially in favor of typical SWDs in comparison with young GAERS (PN57-PN64) which had more SISWDs than SWDs.
Discussion
A new approach to drug screening, including the process of epileptogenesis, may identify new classes of drugs. 22, 23 LEV is a novel AED with potential antiepileptogenic properties, which was discovered using non-conventional drug screening. It suppresses kindling development at doses devoid of adverse effects with persistent reduction in after discharge duration after termination of the treatment. 7 In the SER-model, LEV was administered before the appearance of spontaneous seizures and was terminated at the expected age for seizure expression, which resulted in a lower seizure number in pre-treated animals. 8 In the present study, we found that chronic LEV administration induced a decrease in epileptiform events (SWDs and SISWDs) in young GAERS (PN57-PN60), which persisted immediately following cessation of treatment (PN61-PN64), but not until adulthood.
In GAERS, SWDs strictly correlate with the occurrence of clinical absences, 18 which was also observed in this study. However, behavioral absence seizures can be subtle as they mostly appear during quiet wakefulness. 18 Therefore, EEG recordings were used to quantify the appearance of SWDs. In our study, we found that typical SWDs are rare in young GAERS. Only three out of seven young control GAERS showed typical SWDs on the EEG and none of the LEV-treated animals (n = 8). SISWDs, however, were the most prevalent type of discharge on the EEG during quiet wakefulness. Hence, these more irregular discharges were taken into account to quantify the effect of LEV on epileptiform events. While it is difficult to correlate SISWDs with behavioral arrest because of their short duration (<1.5 s), it can be assumed that these discharges are closely related to SWDs and reflect premature SWDs given their morphological resemblance with typical SWDs and their strong decrease in favor of typical SWDs as the rats grow older.
In this study, epileptiform events (SWDs + SISWDs) were significantly suppressed (difference of 62%) during chronic LEV treatment in young GAERS (PN57-PN60) in comparison with control animals. This is in line with a previous acute study of Bouwman et al., 17 which found a similar difference in SWDs between control and LEV-treated adult rats in the WAG/RIJ model of absence epilepsy.
The LEV-treated animals displayed less SISWDs (up to 81%) than the control group even in the pre-injection hours during PN57-PN60. This could suggest that there was a slowing down of the epileptogenic processes by early chronic treatment (PN23-PN60) with LEV. Yet, the lower number of SISWDs in the pre-injection hours might also be caused by retention of LEV in the brain from previous injections, although LEV was already eliminated from the blood plasma.
Interestingly, there was no acute decrease in SISWDs after injection of LEV (PN57-PN60) and even the opposite could be observed. This is in contrast 408 S. Dedeurwaerdere et al. with previous acute experiments in adult GAERS, in which a clear decrease in SWDs could be observed after a single LEV injection. 14, 16, 17 These studies, which were performed in adult GAERS, 16, 17 report the effect of a first and single LEV injection, while the effect of chronic LEV administration was not investigated.
14 Moreover, several studies dealing with the chronic administration of LEV in animal models of temporal lobe epilepsy report increased functional tolerance towards LEV and some loss of efficacy after prolonged administration. 7, 13, 24 This could be a possible reason for the lack of an acute decrease in SISWDs in rats that were already pretreated.
The acute increase in SISWDs on PN59 and PN60 after LEV administration could represent a flaring up which stabilized again towards the next day. A trend for this phenomenon was also observed in the control group on PN59 (P = 0.066). There was no difference between recording hours during the last 4 days, when the rats were no longer injected with saline or LEV (PN61-PN64). Hence, stress after injection could be a responsible factor for this increase in SISWDs, although the animals were accustomed to the handling procedures.
When treatment was stopped, there was no sudden increase in epileptiform events (SWDs and SISWDs). This is in line with previously performed rat and mice experiments where chronic treatment with LEV did not lead to withdrawal hyperexcitability. 24, 25 During different time points, epileptiform events were still significantly lower (up to 66%) in young LEV-treated GAERS. This difference in number of absence seizures between controls and LEV-treated rats is comparable to the study in the SER model. 8 In the SER study, absence seizures were still decreased 2 weeks after treatment cessation during the 30-min recording period. However, the next week there was no longer a significant difference between the control and LEV-pretreated group. In the study of Glien et al., 13 spontaneous partial seizures in the pilocarpine model of temporal lobe epilepsy were also still decreased 1 week after termination of chronic LEV administration (2 weeks) in certain rats, this was described as a carryover effect.
In both LEV and control group, epileptiform events started to increase on the last days of recording, which can be due to the progressive nature of absence epilepsy in young GAERS. Still, significant lower SISWDs (up to 66%) in the LEV group could be detected on these last days of EEG recording (PN63 and PN64) in comparison with the control group.
Early chronic treatment with LEV in young GAERS might have caused an initial slowing down of the epileptogenic processes, which had persisting effects after treatment termination. The major metabolite of LEV is pharmacologically inactive, and other metabolites are produced at levels below those that are relevant for pharmacological activities. 7 LEV does not interfere with enzyme systems 26, 27 and is washed out rapidly (half-life $2-3 h) after stopping the treatment. 7 As we used a relatively high dose to inject and LEV is already effective in low doses in GAERS, 14 we expect that relevant therapeutic concentrations are present in the blood plasma for 8 h. Hence, the prolonged decrease in epileptiform events on PN61-PN64 is probably not due to a prolonged acute effect caused by accumulated LEV or other metabolites.
Early chronic administration of LEV had no effect on the later expression of SWDs at the age of 4 months. SISWDs have diminished considerably in both groups; this supports its role as premature SWDs. Most likely, after discontinuation of the treatment, epileptogenesis could further progress. To our knowledge, there is only one other study where an AED, i.e., remacemide was chronically administered in young GAERS (PN7-PN25) to establish its effect on SWD development. 28 This study failed to demonstrate an effect of early remacemide treatment on the expression of SWDs in adult GAERS. 28 In the present study, adult GAERS displayed fewer seizures and shorter mean SWD durations compared to previously published experiments in GAERS, which were monitored only for a short period of time. 18 However, these values were similar to a previous chronic experiment performed by our group. 29 This phenomenon of a decrease in seizures during longer recording periods is correlated with the decrease of vigilance resulting in more sleep episodes and less and shorter seizures. 19, 30 Until now, it is not described in what manner LEV exerts its effect on absence seizures in GAERS. LEV has no effect on the T-type voltage-activated Ca 2+ current, 31 a common target for absence epilepsy drugs. A possible effect of LEV that might contribute to its action against SWDs in GAERS could be by progressively decreased firing of the substantia nigra pars reticulata (SNR) neurons. 32 The SNR is not part of the epileptic circuit underlying absence seizures, but it may belong to a system participating in a remote control over seizures. 18 Indeed, highfrequency stimulation of the SNR has been shown to interrupt SWDs in GAERS 33 and intracerebral microinjections of GABA mimetics in the SNR suppress absence seizures. 18 A part of LEV's ability to suppress seizures may origin in its effect on neuronal firing in the SNR, but the anatomical network and molecular mechanisms by which this is mediated remains to be demonstrated. 25 By this way, LEV could suppress SWDs in GAERS, but it is not known if this might interfere with epileptogenesis. In GAERS pups, metabolic increases in SNR compared to non-epileptic control rats were observed, which was suggested to reflect a mechanism of prevention of epileptogenesis in GAERS. 34 
Conclusion
In this study, chronic LEV administration induced a decrease in epileptiform events in young GAERS (PN57-PN60), although this was not obtained by a decrease immediately after injection. This effect persisted partly after cessation of treatment (PN61-PN64), which might reflect a slowing of epileptogenic process due to previous chronic treatment with LEV. However, when LEV-and salinetreated animals grew up, they all developed a similar expression of spontaneous absence seizures.
